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Abstract
Context: Androgen modulation of erectile function (EF) is widely accepted. However,
the use of testosterone replacement therapy (TRT) in men with erectile dysfunction (ED)
has generated an unprecedented debate.
Objective: To summarize the relevant data on the incidence, diagnosis, and manage-
ment of ED coexisting with hypogonadism and to develop a pathophysiology-based
treatment algorithm.
Evidence acquisition: We reviewed the relevant medical literature, with a particular
emphasis on original molecular studies, prospective observational data, and randomized
controlled trials performed in the past 20 yr.
Evidence synthesis: Testosterone modulates nearly every component involved in EF,
from pelvic ganglions to smooth muscle and the endothelial cells of the corpora
cavernosa. It also regulates the timing of the erectile process as a function of sexual
desire, coordinating penile erection with sex. Epidemiologic studies confirm the signifi-
cant overlap of hypogonadism and ED; however, most guidelines do not consider the
differential diagnosis of hypogonadism or the relevance of subclinical disease. Various
clinical tools can help the physician to assess and restore androgen levels in men with
ED. Special attention is given to fertility-sparing treatments, due to the increasing
number of older men desiring fatherhood. The simultaneous use of phosphodiesterase
type 5 inhibitors (PDE5-Is) and TRT has recently been questioned. Originally proposed as
a salvage therapy for nonresponders to PDE5-Is, this approach has been inappropriately
transformed into a combination therapy. Clinical data are consistent when reinterpreted
in the proper framework, whereas molecular evidence remains controversial.
Conclusions: A body of molecular and clinical evidence supports the use of TRT in
hypogonadal patients with ED, although the benefit–risk ratio is uncertain in advanced
age. Critical appraisal of this evidence enabled the development of a pathophysiology-
oriented algorithm designed to avoid inappropriate treatments and support whether to
start with TRT, PDE5-I only, or both. Apparently divergent findings are reconciled when
TRT is correctly indicated. An improved diagnosis and individualized management is
desirable in light of the many available options.
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1. Introduction
Erectile dysfunction (ED) has emerged as an important
marker of cardiovascular (CV) and overall health, indepen-
dently of other known conventional risk factors [1]. Normal
sexual activity throughout the adult lifespan has been
associated with a reduced incidence of CV events, suggesting
a protective role [2]. Coronary artery disease is preceded by
ED in half of the affected subjects, underlining the need for
proper screening [3]. Sexual dysfunction is the most specific
symptom of late-onset hypogonadism (LOH) [4] in the aging
man, a condition also associated with an increased mortality
for CV events [5]. However, ED still remains largely under-
diagnosed and untreated. The Global Study of Sexual
Attitudes and Behavior showed that < 30% of men with ED
had sought medical help, due to high social and personal
barriers [6].
Public awareness of the benefits of phosphodiesterase
type 5 inhibitors (PDE5-Is) has significantly shortened the
time lag between the onset of ED and the seeking of medical
help [7]. The same cannot be said for testosterone replace-
ment therapy (TRT) in LOH, despite the availability of
excellent multifaceted treatment options, due to the long-
standing controversies surrounding safety versus efficacy in
male sexual dysfunction. The scientific community is sharply
divided into those for or against TRT, with a proliferation of
studies with apparently contradictory findings, generating a
debate without comparison in any other hormone deficiency.
These considerations prompted us to perform a critical
appraisal of the major studies of TRT in sexual dysfunction,
focusing on three of the critical questions: (1) Is TRT
worthwhile in ED patients? If so, how and when? (2) Does
testosterone (T) act centrally or peripherally? (3) What are
the underlying facts and beliefs about the combination of
T and PD5-I therapy? Is it safe?
2. Evidence acquisition
We reviewed the relevant medical literature, with a
particular emphasis on original molecular studies, prospec-
tive observational data, and randomized controlled trials
(RCTs) performed in past 20 yr that included the search
terms testosterone or hypogonadism and erectile function
(EF). We provide a systematic review and critical appraisal
of the data (see Supplement).
3. Evidence synthesis
3.1. Hormonal assessment in erectile dysfunction patients
The European Male Ageing Study (EMAS) found that 30% of
European men experienced ED and two-thirds of them were
eugonadal [4]. In representative samples, the prevalence of
hypogonadism ranges between 23% and 36% of ED subjects
[8] and varies according to the cut-off value adopted for the
diagnosis, respectively 7%, 23%, 33%, or 47% for T levels of
<7, 10.4, 12, or 14 nmol/l [9]. These figures, however, are
simple associations that do not imply any causal association
between the two conditions.
Detractors of universal screening of androgen deficiency
in ED subjects point out that, in addition to the known
causes of hypogonadism (Fig. 1), the frequent real or
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Fig. 1 – Causes of reduced androgen levels in men with erectile dysfunction. CNS = central nervous system.
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spurious fluctuations in T levels produce several false
diagnoses. Drugs could also affect T levels (see Supplemental
Table 1). A transient drop in T could be due to acute illness,
and no lower limit of normal is universally accepted. There
is, however, general agreement that total T >12 nmol/l
(>350 ng/dl) does not require replacement therapy,
whereas T <8 nmol/l does eventually merit treatment.
The strength of this consensus is inversely proportional
to the age of the subjects, so replacement therapy for
a baseline T of 10 nmol/l would gain more support in a
40-yr-old man than in a 70-yr-old man. Table 1 provides
suggestions on how to assess gonadal status in ED patients.
A second confirmation of a reduced T level is highly
recommended, possibly including measurement of sex
hormone-binding globulin (SHBG), to enable the calcula-
tion of free testosterone (fT) [10]. Prolactin should also be
assessed in all cases of reduced T values [11].
Surprisingly, most guidelines do not consider the
differential diagnosis of the cause of hypogonadism to be
mandatory in the diagnosis of LOH; as a consequence,
luteinizing hormone (LH) measurement is often considered
unnecessary [10,12]. This oddity is justified by the very high
frequency of a mixed etiology, with an altered hypothalam-
ic-pituitary-gonadal (HPG) feedback loop secondary to age,
comorbidities, and drugs. Measuring LH could be useful not
only for the diagnosis of primary hypogonadism (low T and
elevated LH), often associated with sexual symptoms, but
also to identify ‘‘compensated’’ or ‘‘subclinical’’ hypogonad-
ism [13,14].
The latter condition is characterized by normal or low-
normal T (gray zone) and elevated LH (>9.4 U/l). This
subgroup of subjects, whose number steadily increases with
age, is the largest in the elderly. In addition, young men with
Klinefelter syndrome, the most common numerical chro-
mosomal aberration (47, XXY), affecting 0.2% of the male
population (www.uroweb.org/guidelines) [10], often have
subclinical hypogonadism that later in life becomes overt
primary hypogonadism [15]. The latter cannot be dismissed
as ‘‘functional’’ and is not the consequence of acute
illnesses. Like primary hypogonadism, it is strongly
associated with physical and sexual symptoms, indicating
that when T declines from a previously high-normal to a
low-normal level, the high LH becomes a biomarker for
insufficient androgenization. The finding of elevated LH
thus reinforces the need to consider replacement therapy,
although clinical trials in this subgroup are scarce, and the
data on long-term follow-up are only recently emerging.
Conversely, a very low T in the presence of normal/low LH
may indicate a pituitary tumor, even with a normal
prolactin, and requires pituitary imaging [11].
3.2. Molecular evidence for testosterone dependency of penile
structure, growth, and responsiveness
It is generally accepted that androgens modulate erectile
physiology in humans and animals. Although most of the
animal data are derived from androgen ablation from surgical
castration and gonadotropin-releasing hormone (GnRH)
analogs, a model that can hardly be transferred to ED in
humans, at least one study used, as an experimental model,
hypogonadism induced by a high-fat diet, and the findings
were consistent with the reports from castration studies [16].
Three levels are under T control: the central nervous system
(CNS) nuclei, the spinal motoneurons, and the genital tissues
(Fig. 2). The CNS effects of androgens are complex, mainly
exerted on the release of stimulatory neurotransmitters such
as dopamine, oxytocin, and nitric oxide (NO), controlling
sexual dimorphic development and mating behaviors [17].
At peripheral levels, androgens modulate nearly every
component involved in EF: structure, function, and innerva-
tion of trabecular smooth muscle cells, endothelial function
of penile vessels, and fibroelastic properties of the corpus
cavernosum. However, the molecular pathways involved are
far from understood. In addition, part of the erectile response
to T is centrally mediated, through an effect on sexual desire,
and this dichotomy has split researchers, with some
supporting a predominance of the central over the peripheral
sites of action. Finally, animal studies have shown species-
specific differences and were performed after castration, a
model very different from hypogonadism in men, generating
uncertainty that is further complicated by the paucity of
available human data.
3.2.1. The nitric oxide and adrenergic pathways
Most animal studies agree that castration caused a rapid
drop in intracavernous pressure due to both reduced
arterial inflow and altered veno-occlusion during stimulat-
ed erections [18]. In rats, castration is associated with a
Table 1 – Checklist for the assessment of gonadal status in patients with erectile dysfunction
1. Check for hypoactive sexual desire, reduced frequency of nocturnal erections, or delayed ejaculation: All increase the likelihood to detect hypogonadism.
2. Use questionnaires/structured interviews: the Androsiedy, St. Louis University Androgen Deficiency in Aging Males, the Aging Male Scales, the Massachusetts
Male Aging Study, and the European Male Ageing Study Sexual Function Questionnaire.
3. Measure prostate volume: A volume lower for age increases the likelihood of detecting hypogonadism.
4. Ask about seminal fluid: Low volume (hypoposia) may be a sign of hypogonadism.
5. Check T in morning: Blood samples should be obtained in a fasting state, between 8 AM and 11 PM.
6. Ask about sleeping: T measurement should be done after a good night’s sleep.
7. Ask about alcohol abuse. Ask about drugs (see Supplemental Table 1).
8. Repeat T measurement: It is always good to confirm T a couple of weeks later, together with the assessment of luteinizing hormone and prolactin.
9. Don’t forget binding proteins: In obesity, metabolic syndrome, type 2 diabetes. or hyperthyroidism or if patients were currently treated with antiepileptic
drugs, check for SHBG levels and calculate the fT according to the Vermeulen formula (http://www.issam.ch/freetesto.htm). A calculated free T <65 pg/ml
is associated with ED [4].
10. The measurement of fT trough radioimmunoassay is unreliable, and it must not be evaluated.
ED = erectile dysfunction; fT = free testosterone; SHBG = sex hormone-binding globulin; T = testosterone.
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rapid reduction in neuronal nitric oxide synthase (nNOS)
activity [19] and pelvic ganglion activity [20]. This is almost
completely reversed by NO, suggesting that NO generation is
a major acute effector of androgens (Fig. 2). However, reports
of nNOS response differ significantly, with some studies
showing an increased activity in rats but no change in protein
expression [19] and others showing no effect in rabbits [21].
Studies performed in L-NAME–treated animals (a nitric oxide
synthase [NOS] inhibitor), revealed some additional mecha-
nisms involved in the androgen regulation of EF. Interesting-
ly, this NO-independent mechanism still appears to require
cyclic guanosine monophosphate (cGMP) generation, critical
to both NO-independent and NO-dependent pathways [22].
Non-NO–mediated androgenic effects seem to be exerted
mainly on the veno-occlusion mechanism.
Sensitivity to neurotransmitters is another possible target
of androgens (Fig. 2). In rats, castration appears to increase
the a1-adrenergic responsiveness of the cavernosal smooth
muscle cells [23]. Surprisingly, in rabbits the a1-adrenergic
receptors seem to be downregulated by castration and
restored by androgen replacement [21]. Castration in rats is
also associated with a decreased density of nonadrenergic-
noncholinergic (NANC) innervating fibers and reduced
NANC-mediated relaxation in isolated corpus cavernosum
strips, but again, not in rabbits, confirming interspecies
differences [21]. In summary, nNOS activity seems to be the
major target of androgens [19,20], followed by opposite
regulation of NANC and a1-adrenergic signaling [21].
3.2.2. The cyclic guanosine monophosphate-phosphodiesterase
type 5 pathway
A number of in vitro animal and human studies found that
PDE5 expression in the penis is upregulated by androgens
[21,24,25]. This finding generated a paradox because an
increase in this enzyme should exert an inhibitory effect
on penile tumescence. However, the latter observation fits
well with various clinical observations, and the authors
suggest that androgens play a dual role in the erectile
process by controlling both pro-erectile and antierectile
signaling pathways. This has also been claimed to explain
the neutral effect of hypogonadism on human erections,
as a net result of decreased cGMP generation (lower NO
activity) accompanied by reduced cGMP degradation
(lower PDE5 activity).
However, studies have questioned the androgenic regu-
lation of PDE5 in the penis, suggesting that the lower levels
observed after androgen deprivation are biased by the overall
reduction in smooth muscle content [26]. Attempts to
extrapolate data from different cell types and tissues,
including prostate or Leydig cells, did not help resolve the
question, with divergent effects ranging from null to up- or
even downregulation of PDE5 by androgens [27]. For
example, in the rabbit prostate, it was recently demonstrated
that metabolic syndrome–induced low T is associated with
an upregulation of PDE5 reversed by T supplementation [28].
Sustained cGMP levels are crucial for any androgenic effect
on penile erection [22]; whether this is a direct [21,24,25] or
indirect [27,28] mechanism remains controversial.
3.2.3. Penile innervation and structure
The data just presented suggest that a major effect of T is on
the postganglionic parasympathetic neurons, or even further
upstream, within the autonomic nervous system (Fig. 2). A
more complex pelvic neuronal activity is supported by the
fact that the effects of castration on penile hemodynamics,
including NOS activity, can be transiently reversed in vivo by
short-term electrical stimulation of the cavernosal nerve
[19]. Most studies agree that castration produces changes in
[(Fig._2)TD$FIG]
Fig. 2 – Sites of action of androgens in male sexual function. Blue arrows and dotted blue circles highlight the targets of testosterone. Ach = acetylcholine;
Ca2+ = calcium; cAMP = cyclic adenosine monophosphate; cGMP = cyclic guanosine monophosphate; eNOS = endothelial nitric oxide synthase;
ET = endothelin; GC = guanylate cyclase; GTP = guanosine triphosphate; IP3 = inositol triphosphate; K
+ = potassium; NANC = nonadrenergic-
noncholinergic; NO = nitric oxide; PDE5 = phosphodiesterase type 5; PGE = prostaglandin E; AC = adenylate cyclase; NE = norepinephrine;
PLC = phospholipase C.
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the critical balance between trabecular smooth muscle and
connective tissue. Androgen deprivation results in pro-
grammed trabecular smooth muscle cell death (apoptosis)
and an increase in the extracellular matrix [21]. Androgen
deprivation is also associated with the accumulation of fat-
containing cells (fibroblasts or preadipocyte-like cells),
especially in the subtunical region of the corpus cavernosum,
thus contributing to impaired veno-occlusion [29]. According
to the neuronal circuitry hypothesis, the main role of
androgens is to support the adequate neuronal stimulation
of the corpora cavernosa, also necessary to maintain tissue
structural integrity and the differentiation of penile mesen-
chymal stem cells. The latter hypothesis is supported by the
similarities between penile fibrotic changes developing after
castration, in animals, and those after denervation following
prostate surgery, in men.
In humans, T influences penile development, mainly as a
result of extracellular stromal expansion [30]. Postnatal
penile length and growth rate also seem to be correlated with
the T surge occurring in the first 3 mo of life (mini-puberty)
[31]. However, no further correlation is seen in postpubertal
adults. Most studies agree that androgen sensitivity and
androgen receptor expression vary with age and stage of
penile development. Whether or not this mechanism is
primarily regulated by androgens remains controversial. The
few human studies failed to document this feedback,
suggesting that penile growth cessation after puberty
depends on other, nonandrogen-dependent mechanisms
[30]. Thus androgens seem necessary to maintain the
fibroelastic properties of penile tissues, at least in animal
models [19,21,29]. Studies in humans suggest that androgens
are also involved in prepubertal penile growth [30,31],
although other independent mechanisms control growth
cessation [30].
3.2.4. 5a-reductase inhibitors and erectile function
Following a proliferation of studies in the 1990s, interest in
androgen action in penile physiology gradually diminished.
However, attention has been renewed by the discovery that
a group of young subjects developed persistent diminished
libido and ED as a consequence of early exposure to
5a-reductase inhibitors (5-ARIs) [32]. This condition,
termed postfinasteride syndrome, seemed to occur in a
small, but not insignificant, subgroup of young subjects
who had taken a 5-ARI for alopecia (although similar
symptoms can also develop in patients taking a 5-ARI for
benign prostatic hyperplasia). The severity of symptoms
seems to correlate to an early intake at the end of pubertal
development, at a stage when the effects of androgenic
activity are still peaking. The 5-ARI transforms not only
T but also other metabolites that can in turn be converted
into a subclass of neuroactive steroids with distinct
physiologic actions.
In animal models, 5-ARIs have been associated with
reduced EF, with marked structural and functional altera-
tions in penile tissue contributing to penile fibrosis that is
mainly exerted through a modulation of cholinergic and
adrenergic sensitivity, with no apparent change in PDE-5
[33]. The depressive symptoms developed by 5-ARI users
who experienced sexual dysfunction are consistent with
former animal studies showing that androgenic regulation
of sexual activity is partially controlled through a modula-
tion of reflexes of social behaviors [34] that goes well
beyond libido. It is also known that different androgen
thresholds are necessary to activate copulatory behavior
and penile reflexes in rats, which are significantly increased
in animals prenatally exposed to alcohol, stress, or
endocrine disruptors [35]. The hypothesis of a dynamic
reset of central threshold values could explain, at least in
part, the androgen insensitivity of aging men chronically
exposed to drugs and diseases.
3.3. Association between testosterone and erectile function
in men
Most animal studies suffer from a short observational period
following castration and androgen administration, which
may influence nerve and tissue remodeling. Conversely, most
human studies are cross sectional and show divergent
results. Some describe a significant association of androgens
with various measures of EF [36,37]; others do not [38]. Most
of the early studies were retrospective, underpowered,
uncontrolled for comorbidities, body mass index, and SHBG,
and weak on the methods used to assay hormones. The recent
EMAS study, a sufficiently large prospective study using mass
spectrometry, shed some light on this controversial issue
[39]. The study found that total T is significantly associated
with overall sexual function, and fT with ED and masturba-
tion frequency, independently of 17-b-estradiol (E2) or
dihydrotestosterone. More importantly, it identified a cut-
off of 8 nmol/l above which any further increase in circulating
T lost any positive correlation.
These findings are in line with previous studies showing,
in a human model of endogenous T suppression by GnRH
agonists, a dose response consistent with the existence of a
T threshold effect [40], and others showing that variation of
T levels within the normal range had no effects on sexual
function [41]. However, some authors have pointed out that
hypogonadal men may have near-normal sexual activity
[37]. Overall, dose–response studies seem to suggest that the
androgen dependency of EF is maintained at threshold values
far below those required to maintain the function of other
target organs. This has been demonstrated in otherwise
healthy men with low T, but it does not automatically
translate to elderly men with comorbidities, in whom these
thresholds may be reset.
The EMAS study also showed that E2, but not T, correlated
with the psychological symptoms of male aging, confirming
the findings of Basar et al. [42]; both these studies found a
robust independent correlation between E2 and sexual
dysfunction–associated distress. Another study found that
T was associated with somatized anxiety only in the older
men with ED [36]. These aspects are most novel in light
of the recently introduced concept of compensated or
subclinical hypogonadism [13] (Fig. 1). In fact, subclinical
hypogonadism is also strongly associated with physical and
sexual symptoms, indicating that when T in men declines
from a previously high-normal to a low-normal level, the
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high LH becomes a biomarker for insufficient androgeniza-
tion [13,14].
3.4. Effects of treating erectile dysfunction in hypogonadal men
using testosterone
Normal men probably have more androgens than are
necessary, in the short term, for normal sexual activity.
Acute, complete androgen withdrawal is unequivocally
associated with loss of sexual interest and erectile failure.
These symptoms are promptly reversed by the administra-
tion of a small amount of T. In the 1980s, Bancroft and Wu
performed the pivotal studies to discriminate central versus
peripheral effects, demonstrating that in acute settings,
erectile capacity in response to visual stimulation is less
sensitive to androgen than is sexual interest, fantasies, and
cognitive sexual activities [43].
Several clinical trials documented a significant improve-
ment in erections and sexual function in hypogonadal men
[44–47]. Uniquely among hormone replacement studies, the
non–placebo-controlled trials are often dismissed as not
evidence based. The few available RCTs were reviewed in
three distinct meta-analyses showing a large effect of TRT on
libido in men with reduced androgen levels, and a small effect
on sexual satisfaction and various parameters of EF in men
with low to normal T levels [8,48,49]. The first one reports
the positive effect of TRT on EF in men with mean T levels
<10 nmol/l (standardized mean difference [SMD]: 1.8; 95%
confidence interval [CI], 0.31–3.43) [48]. In a subsequent one,
Bolona et al. [49] found a small yet significant effect (SMD:
0.34; 95% CI, 0.03–0.65) on EF of men with low-normal
T levels, and a greater effect in the subgroup of young
subjects (SMD: 1.80; 95% CI, 1.0–2.7), emphasizing a role of
aging as a possible moderator of ED responsiveness to TRT.
In particular, a nonsignificant effect was found in older men.
In the last available meta-analysis, Tserstvadze et al. [8]
concluded that results of any TRT were inconsistent
regarding their effects on EF, degree of erection, or improved
erection. Due to these contrasting results, we systematically
analyzed all the data available so far concerning RCTs,
reported in the Supplement (Supplemental Table 2).
The 20 identified RCTs showed large discrepancies in
clinical response, with individual variations related to bias in
the studies, age, type, and potency of T preparation, outcome
measures, and comorbidities of the recruited subjects. No
effect was found in men with T>12 nmol/l, whereas in 10 of
the 14 RCTs performed in hypogonadal men, a beneficial
effect of TRT on EF was found. Among studies providing crude
International Index of Erectile Function (IIEF) data [45,46,
50–53], TRT produced a weighted mean improvement of
baseline IIEF score of 39% (range: 22–79%) corresponding to a
weighted mean delta of IIEF-5 of 4.32  2.01 points (range:
3–8). The European Association of Urology (EAU) guidelines for
male sexual dysfunction gave a level of evidence (LE) of 1b (at
least one RCT) and a grade of recommendation (GR) of B (based
on well-conducted but not randomized trials) to the need to
treat at first any ‘‘curable cause of ED’’ including hypogonadism
[12]. The EAU guidelines on hypogonadism gave an LE of 3
(based on well-designed and nonexperimental studies) and a
GR of B the opportunity to treat ‘‘decreased libido and erection’’
with testosterone [10].
Another relevant aspect that has only recently received
attention is the time course of T effects (ie, the length of
treatment necessary to achieve the maximum result). A
systematic analysis showed effects on libido, ejaculation,
and sexual activity within just 2–3 wk, whereas effects on
EF may require up to 6 mo to become detectable by IIEF [54].
Recent RCTs showed that a statistically significant improve-
ment in IIEF, detectable at 6 mo as marginal changes
[46,47], can achieve a further significant increase after
12 mo of an open-label treatment [45,46]. Taken into
account these limitations, the time course of TRT has been
claimed to explain some negative findings in the experi-
mental human studies on T/sex thresholds that were mainly
performed in the acute settings (weeks), as opposed to
penile tissue recovery that may require several months.
Few studies have explored whether there is any
difference between raising T by exogenous steroid admin-
istration or by Leydig cell stimulation. This is more relevant
in view of the increasing proportion of aging men with ED
who still wish to achieve fatherhood. Buvat showed that
raising T by human chorionic gonadotropin (hCG) is
associated with an increase in sexual activity in half of
men with normal baseline T levels [55].
Guay [56] showed that the normalization of androgens
by clomiphene produced a satisfactory response in 39% of
all treated men, with younger subjects (<55 yr) responding
better than older men and men with comorbidities. One of
the most interesting findings was that pituitary stimulation
in secondary hypogonadism, even if related to acute or
chronic illness, can be used transiently while the underlying
problem is corrected. In addition, a recent study showed
that clomiphene citrate is also safe and effective for the
long-term management of male hypogonadism [57],
making it suitable for men seeking fertility. Alternatively,
the adjunct of low-dose hCG to TRT prevents spermatogen-
esis suppression and can be used in impotent hypogonadal
men in whom fertility remains an issue [58] (Fig. 3).
To summarize, increasing androgen levels, either by
hormonal replacement [8;45–53] (Supplemental Table 2) or
by the stimulation of Leydig cells [55–57] is superior to
placebo in improving various sexual outcomes, but the
magnitude and timing of effects [45,46,54] are highly
variable and difficult to predict. To improve the response, a
combined treatment could also be considered (Fig. 3). On
the contrary, when baseline T levels are normal, no
beneficial effects has to be expected from TRT.
3.5. Effects of treating erectile dysfunction in hypogonadal men
using a phosphodiesterase type 5 inhibitor
PDE5-Is are rapid and potent drugs acting directly on the
mechanisms of erection, and they have changed the
expectation of both physicians and patients about how to
improve EF. The fact that sexual activity per se can affect
T levels has been hypothesized since the 1970s. However, the
first formal studies by Jannini and colleagues showed that
restoring EF by nonhormonal therapies (eg, psychotherapy,
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intracavernous injections) in various settings can raise
circulating T by 30–40% of baseline values [59]. The same
effect was subsequently demonstrated with PDE5-I therapy
[60]. An attempt was made to investigate whether this was a
drug-specific effect. However, the increase in the frequency
of sexual intercourse, by whatever means this was achieved,
was the best predictor of androgen recovery [59,60]. This
finding was confirmed in a large RCT, which found that a
4-wk run-in of PDE5-I in hypogonadal men significantly
raised T levels by a mean of 4 nmol/l [61].
The consequences of being unable to achieve full
penetration are thought to be the major cause for down-
regulation of the neurohormonal mechanism that controls
the GnRH pulse generator and in such patients causes
hypogonadism [13]. However, recent studies show that
PDE5 is expressed by Leydig cells and its inhibition can
increase hormone release [27], suggesting that a direct
testicular action is also possible. Based on the available
studies, the increase in T that can be expected after PDE5-I
use is in the range of 3–6 nmol/l [59,61]. These data support
a possible role of PDE5-I as the sole treatment in selected
men presenting with ED and reduced T levels (Fig. 3).
However, the use of only a PDE5-I may be insufficient in
other cases: A young man with severe hypotestosteronemia
is unlikely to restore eugonadism simply by increasing his
sexual performances with a PDE5-I. In addition, given the
proposed mechanisms, subjects with an elevated LH are
unlikely to respond to a PDE5-I, given that the feedback is
already enhanced and Leydig cells might be dysfunctional.
3.6. Effects of combining testosterone and phosphodiesterase
type 5 inhibitor
Combination therapy with PDE5-I and T is highly debated,
with strong reasons in favor or against it asserted by the
various researchers. PDE5-Is are effective, but regardless of
their pharmacokinetics or the regimen used, none have
been shown to cure ED. Thus they remain symptomatic
drugs [60]. In hypogonadal men, PDE5-Is alone might be
sufficient to improve erections, but they are inadequate to
address all domains of sexual function and the systemic
complication of hypogonadism (Fig. 3). Epidemiologic
studies show that sexual dysfunction is one of the main
symptoms causing hypogonadal men to seek medical help
[4]. For this reason, once treated with PDE5-Is, they may no
longer be interested in correcting their underlying androgen
deficiency. Symptomatic pro-erectile treatment will thus
leave such men otherwise untreated and exposed to a
greater risk of osteoporosis, diabetes, dyslipidemia, obesity,
and CV morbidity and mortality [62].
Although PDE5-I may effectively treat erections, as
measured by the IIEF, they cannot address the ancillary
sexual signs and symptoms associated with hypogonadism,
such as low libido, reduced ejaculatory volume, and other
[(Fig._3)TD$FIG]
High LH Low/normal LH
T<12 nmol/L
Young men
without co-
morbidies
Old men
with co-
morbidies
TRT only
Start TRT + PDE5-I
“combinaon
therapy”
PDE5-I only
Revaluate T
within 1 mo
PDE5-I only
Follow-up  for
later T decline
Add up TRT
(independently of
response to PDE5-I)
T<12 nmol/L T>12 nmol/L
If subsequent failure to PDE5-I
consider a short trial of
TRT + PDE5 “salvage therapy”
Men of any age complaining of ED
Obtain two separate T and LH measurements
Discordant results
between the two
measurements
High LHLow/normal LH
T>12 nmol/L
PDE5-I only
orConsider hCG
clomiphene in men
desiring children
Fig. 3 – Pathophysiology-oriented algorithm for the treatment of erectile dysfunction in men with altered circulating testosterone levels. ED = erectile
dysfunction; hCG = human chorionic gonadotropin; LH = luteinizing hormone; PDE5-I = phosphodiesterase type 5 inhibitor; T = testosterone;
TRT = testosterone replacement therapy.
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symptoms [63]. Therefore, even if erection hardness is
tangibly improved, the subject’s sex life may not be fully
restored.
3.6.1. Testosterone replacement therapy and phosphodiesterase
type 5 inhibitor: ‘‘salvage’’ versus ‘‘combination’’ therapy
The fact that ED and hypogonadism often coexist in aging
men led some authors to explore whether the combination
of a PDE5-I and TRT would elicit beneficial effects. Originally
proposed as ‘‘salvage therapy’’ for nonresponders or PDE5-I
failures [64,65], this approach has been improperly
transformed into a ‘‘combination’’ therapy, with the aim
of adding the beneficial effects of each drug on EF to one
another. The post hoc analysis of the TADTEST trial showed
that below a threshold of 10.4 nmol/l (300 ng/dl) for total T,
the efficacy of PDE5-I is suboptimal [65]. The salvage
rate that could be obtained in hypogonadal men, failing a
PDE5-I, was highly variable ranging from 32% to 100% [66],
with some sort of improvement expected in about two-
thirds of treated patients.
However, this approach was recently questioned by a
large study from Spitzer and colleagues, designed to address
whether TRT has any additional effect when erection score
is maximized by a PDE5-I [61]. The study definitively
confirmed that there is no need to add T when EF is already
being restored by a PDE5-I, other than to treat the systemic
complications of hypogonadism. However, the trial was not
powered to address any role of T as a salvage therapy
because there was a significant increase in T during the
sildenafil optimization run-in. This resulted in a large
percentage of the study subjects with T >12 nmol/l at
randomization, and the overall number of PDE5-I failures
was low.
Whether or not TRT should be offered to all men who
remain hypogonadal while failing PDE5-I therapy remains
debated (Fig. 3). TRT might rescue some of these failures by
boosting all aspects of men’s sexual health, including
several minor targets, from libido to ejaculation volume and
the so-called nonspecific mood-lifting properties. Putative
benefits are unlikely to be exerted through an increase in
erection hardness, the parameter scored by the IIEF-5,
but rather by subtle changes in cavernous smooth muscle
cells, libido, motivation, and ejaculation [63] that may
also be important, even if not measured by the IIEF. In
summary, TRT should be used first in some subgroups of
patients, especially in young men with organic hypogonad-
ism, whereas others may benefit from the use of combina-
tion therapy from the beginning (Fig. 3). Yet a relevant
group of ED hypogonadal patients could safely be started on
PDE5-I monotherapy and, in those who retain persistently
low T levels, TRT should be offered as a salvage therapy for
PDE5-I failure (Fig. 3).
3.7. How and when to increase testosterone levels in erectile
dysfunction patients
If the cause of ED is low T, as is often the case in young
hypogonadal men, androgen replacement is the cure, and
monotherapy often suffices. This can be achieved with the
daily administration of any of the several available topical
formulations (Table 2). The cutaneous side effects of the
latest gels and solutions are insignificant, although they are
more common with older patches. Treatment of severe
hypogonadism in younger men might require higher doses
than those delivered by the standard gel sachets (usually
50 mg). T monitoring is thus highly recommended to
achieve the desired level. Formulations in adjustable
dispensers are more suitable for dose titration [67]. The
recently introduced long-acting T (available in Europe)
overcomes the compliance problems associated with daily
administration, offering a treatment that is particularly
suitable for young men [47]. Administration once every
12–14 wk frees the patient from considering himself
abnormal as a daily application would inevitably recall. It
also avoids the problems of washing off the gel or the skin
irritations associated with sweating of more physically
active men. Long-acting T undecanoate injections have been
reported as safe and reliable in both young and older
subjects [47], but given the uncertainty of the diagnosis, the
variability of T measurement, and the unpredictable
hematocrit response, it is advisable to first use a 3-mo
run-in with a short-acting gel. For men who intend to father
children, a number of alternative options are available
including clomiphene or b-hCG (Fig. 3).
When ED is not due solely to hypogonadism but also to a
concomitant vascular or metabolic disorder, TRT alone is
insufficient to restore erection, and PDE5-I use is required.
The effects of androgens on erection are in fact slow and
progressive [45,46], and they are often imperceptible to the
patient if not administered over a long time [54]. Young
hypogonadal men in a stable relationship are often eager to
wait and see if the effects of testosterone ‘‘cure’’ their
erection while benefiting from the spurt in libido, rather
than immediately starting a PDE5-I, perceived as a drug for
older men. However, those who experience repeated
failures or have an unstable relationship may ask for a
drug enabling their rapid achievement of erection, thus
counteracting their performance anxiety. Cost is another
issue. Although considered very safe, TRT requires periodi-
cal monitoring of blood parameters (Table 3). This adds to
the cost of the T and any PDE5-I. At least hematocrit
and prostate-specific antigen (PSA) in addition to T are
generally performed at least every 6 mo [10]. One aspect
that deserves mention is the issue of the polymorphism of
androgen receptor, in particular the length of CAG repeats
that affect the efficiency of receptor signaling that account
for a significant variability in the thresholds of symptoms
and, more importantly, the responsiveness to TRT (see
Supplement) [68].
3.8. Proposal of a treatment algorithm
The collected evidence shows that TRT monotherapy
restores sexual function in some cases, whereas in others
a PDE5-I only improves T levels. The combination of a
PDE5-I and TRT has been tested in hypogonadal men not
responding to androgens or in those with persistent
hypogonadism following PDE5-I failure. A critical appraisal
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reveals that the discrepancies among studies are related to
inclusion criteria and outcome measures. TRT monother-
apy, PDE5-I only, and the combination of the two could all
be valid options for different cases of ED coexisting with
hypogonadism. To support physicians in the selection of the
best treatment strategy, we have developed a multistep
treatment algorithm presented in Figure 3.
3.9. Safety issues and future perspectives
The controversies surrounding TRT for ED have been
magnified by uncertainty on its safety. The two major
concerns are the prostate and the CV system. The mistake of
translating the effects of androgen deprivation in advanced
prostate cancer (PCa) to the effects of androgen replace-
ment in noncancerous prostate diseases has generated a
number of unjustified fears. The saturation model proposed
by Morgentaler and Traish [69] finally reconciled both ends
of androgen’s effects on prostate growth. A survey of most
cited guidelines from international societies is reported in
Table 4; all statements offer reassurances on the prostate
safety of TRT, once contraindications, counseling, and
required screening are respected. A collaborative study
comparing 3886 men with incidental PCa with 6438
controls from 18 studies concluded that endogenous
concentrations of sex hormones are not associated with
the risk of PCa [70]. In contrast, growing evidence indicates
that androgens exert an anti-inflammatory effect on human
prostatic stromal cells. This could be useful in the treatment
of lower urinary tract symptoms, possibly in combination
with a PDE5-I [28;71].
Table 2 – Available preparations to treat male hypogonadism
Compound Dosage Advantages Disadvantages
Oral agents
T undecanoate 120–240 mg
2–3 times daily
-Oral
-Adjustable dose
-Variable T levels and clinical responses
-Must be taken with meals containing at least 20 g of lipids
Intramuscular agents
Testosterone enanthate 250 mg every
2–3 wk
-Low cost -Wide fluctuations in T levels
-Multiple injections
-Relative higher risk of polycythemias
Testosterone cypionate 200 mg every
2–3 wk
-Low cost -Wide fluctuations in T levels
-Multiple injections
-Relative higher risk of polycythemia
T propionate 100 mg every
2 d
-Low cost -Wide fluctuations in T levels
-Multiple injections
-Relative higher risk of polycythemias
T undecanoate in castor oil 1000 mg every
10–14 wk
-Efficient T normalization
-Long lasting
-Better compliance
-Pain at injection site
-Requires injection training
Subcutaneous agents
Surgical implants 4/6 200-mg implants
lasting up to 6 mo
-Treatment only twice per year -Placement is invasive
-Risk of extrusion and site infections
-Requires trained operator
Controlled release T buccal formulation agents
T buccal 30 mg 2 times daily -Oral -Possible oral irritation
-Twice-daily dosing
-Unpleasant taste
Transdermal agents
T patches 5–10 mg
1 daily
-Mimics circadian rhythm
-Simple administration
-Skin irritation
-Daily administration
-Noisy/sport/washing issues
T gel
1–2%
40–80 mg
1 daily
-Efficient T normalization
-Flexible doses
-Less skin irritation
-Possible transfer during intimate contact
-Daily administration
Underarm testosterone
2% solution
60–120 mg
1 daily
-Efficient T normalization -Possible transfer during intimate contact
-Daily administration
T gel
1.62%
20.25–81 mg
1 daily
-Efficient T normalization
-Flexible doses
-Less skin irritation
-Lower amount to apply
-Possible transfer during intimate contact
-Daily administration
T = testosterone.
Table 3 – Safety monitoring during testosterone replacement
therapy
Baseline 3–6 mo 12 mo Subsequent
screening
periodicity
Testosterone + + 6–12 mo
LH/FSH/PRL + –
Hematocrit/Hemoglobin + + + 6–12 mo
Glycemia/Lipid profile + + 12 mo
PSA + + 6–12 mo
DRE + + + 12 mo
Bone densitometry scan + 24 mo
DRE = digital rectal examination; FSH = follicular stimulating hormone;
LH = luteinizing hormone; PRL = prolactin; PSA = prostate-specific antigen.
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Table 4 – Survey of currently available guidelines, recommendation, and statements addressing prostate safety of testosterone replacement
therapy
Target population Issuing society Year Statement Level of
evidence
Grade of
recommendation
Risk of newly developed prostate cancer
Testosterone deficiency ISSM [79] 2013 There is no compelling evidence that high baseline
endogenous androgens or TRT cause prostate cancer or
prostate cancer progression in the noncastrated man.
1a –
Male Hypogonadism EAU [80] 2012 Randomized controlled trials support the hypothesis
that TRT does not result in changes in prostatic
histology.
1b –
Late-onset hypogonadism ISA, ISSAM,
EAU, EAA, ASA [10]
2009 At the present time, there is no conclusive evidence
that TRT increases the risk of prostate cancer or BPH.
There is also no evidence that T treatment will convert
subclinical prostate cancer to clinically detectable
prostate cancer.
4 C
Patients with locally advanced prostate cancer
Testosterone deficiency ISSM [79] 2013 T therapy is contraindicated in men with clinical
evidence of prostate cancer or any prostatic
abnormality suspicious of cancer until more evidence
of safety is available.
5 C
Male hypogonadism Endocrine Society [81] 2010 We recommend against T therapy in patients with
prostate cancer.
Low Strong
Late-onset hypogonadism ISA, ISSAM,
EAU, EAA, ASA [10]
2009 There is evidence that T can stimulate growth and
aggravate symptoms in men with locally advanced and
metastatic prostate cancer.
2a A
Patients successfully treated for localized prostate cancer
Testosterone deficiency ISSM [79] 2013 Men successfully treated for prostate cancer and
experiencing confirmed, very symptomatic T deficiency
may be candidates for TRT, after a prudent interval
(depending on the type of cancer treatment), if there is
no evidence of residual disease, and if they had an
initial tumor contained in the prostate gland that was
not high-grade Gleason score.
The risks and benefits must be clearly understood by
the patient, and the follow-up must be particularly
careful. Informed consent must be obtained. Safety data
are limited.
4 C
Male hypogonadism EAU [80] 2012 In patients operated on for localized prostate cancer,
TRT should not start before 1 yr of follow-up without
PSA recurrence has been completed.
4 B
Late-onset hypogonadism ISA, ISSAM,
EAU, EAA, ASA [10]
2009 Men successfully treated for prostate cancer and
experiencing confirmed symptomatic hypogonadism
are potential candidates for TRT after a prudent interval
if there is no clinical or laboratory evidence of residual
cancer. The risk and benefits must be clearly discussed
with and understood by the patient, and the follow-up
must be particularly careful.
2b C
Patients with severe LUTS due to BPH
Testosterone deficiency ISSM [79] 2013 Men with severe symptoms of bladder outlet
obstruction should not be started on TRT without prior
improvement of the comorbid condition.
5 C
Male hypogonadism Endocrine Society [81] 2010 We recommend against TRT in patients with severe
lower urinary tract symptoms (IPSS >19)
Very low Weak
Late-onset hypogonadism ISA, ISSAM, EAU,
EAA, ASA [10]
2009 Severe symptoms of LUTS evident by a high IPSS (>21)
due to BPH represent a relative contraindication (there
are no compelling data to suggest that TRT causes
exacerbation of LUTS or promotes acute urinary
retention). After successful treatment of lower urinary
tract obstruction, this contraindication is no longer
applicable.
4 C
ASA = American Society of Andrology; BPH = benign prostatic hyperplasia; EAA = European Academy of Andrology; EAU = European Association of Urology;
IPSS = International Prostate Symptom Score; ISA = International Society of Andrology; ISSAM = International Society for the Study of Aging Male;
ISSM = International Society for Sexual Medicine; LUTS = lower urinary tract symptoms; PSA = prostate-specific antigen; T = testosterone; TRT = testosterone
replacement therapy.
1a = evidence obtained from meta-analysis of randomized trials; 1b/2a = evidence obtained from at least one randomized trial. 4 = evidence obtained from
expert committee reports or opinions or clinical experience of respected authorities. A = based on clinical studies of good quality and consistency addressing
the specific recommendations and including at least one randomized trial; B = based on well-conducted clinical studies, but without randomized clinical trials;
C = made despite the absence of directly applicable clinical studies of good quality.
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3.9.1. Testosterone replacement therapy after successful treatment
for prostate cancer
ED is a frequent complication of treatment for PCa. A current
debate is whether men who have been surgically treated for
localized PCa, without evidence of active disease and
showing symptoms of T deficiency, can be considered for
TRT. The EAU guidelines conclude that ‘‘there is limited
evidence suggesting that such treatment may not pose an
undue risk of prostate cancer (PC) recurrence or progres-
sion.’’ Yet only scarce data are available.
For this reason, we performed a systematic review of
published reports (Supplemental Table 3). Among a total of
179 men treated with TRT after radical prostatectomy, only
4 developed a biochemical recurrence (2.2%) within 2 yr of
TRT (only 1.1% had a PSA elevation>0.2 ng/ml). Men treated
with different modalities, other than radical prostatectomy,
showed a higher recurrence rate. Although a statistically
significant increase in PSA can been seen in TRT-treated men,
independently of risk stratification, in most cases such an
increase was not supportive of PCa recurrence. Multivariate
analysis revealed that a higher baseline PSA level was the
most relevant risk factor for disease progression, whereas
Gleason grade, duration of TRT, and level of T achieved
during TRT were not prognostic factors. A small consistent
beneficial response on EF is reported in the few studies
investigating this issue. A larger number reported improve-
ment in energy, mood, and libido. However, the retrospective
nature of these reports and the lack of placebo control limit
their value.
3.9.2. Testosterone replacement therapy, phosphodiesterase type 5,
and the cardiovascular system
Regarding CV safety, although a single study reports
increased CV events in elderly men with limited mobility
[72], meta-analyses on TRT for ED showed no increased CV
risk [48,49]. Similarly, two other meta-analyses on TRT
given for reasons other than ED found no significant effect
with respect to specific CV outcomes: arrhythmia, coronary
bypass surgery, myocardial infarction, and heart failure
[73,74]. However, a more recent meta-analysis [75] found a
statistically significant increase in ‘‘composite’’ CV-related
event (odds ratio: 1.54; 95% CI, 1.09–2.18), as observed
in the Testosterone in Older Men trial [72]. These data
suggest that TRT is not entirely risk free in older men with a
higher composite risk of CV events. In this respect, the
increase in hematocrit remains the most significant
identified change with an impact on the CV system. These
safety warnings contrast with several studies showing that
androgens can counteract the features of metabolic
syndrome [5], thus determining a considerable reduction
in CV risk [62,76]. However, the CV abnormalities seen in
hypogonadal men with Klinefelter syndrome (ie, left
ventricular diastolic dysfunction) are not entirely reversed
by TRT. This suggests that delayed or suboptimal TRT can
produce irreversible changes [77] or, alternatively, that
cardiac dysfunction is independent of hypogonadism. The
need for prompt treatment of the CV abnormalities
associated with ED and hypogonadism was demonstrated
by Montorsi et al., who found that severe ED precedes
coronary artery disease by about 2–3 yr [3]. Finally, recent
studies demonstrated that chronic PDE5-I could also be
beneficial to counteract cardiac remodeling [78] and lower
urinary tract symptoms [71], showing that treating ED
could have potential beneficial effects on various organs
and systems.
4. Conclusions
All subjects with an organic cause of primary or secondary
hypogonadism, especially if young and with a significant
drop in T levels, should receive TRT as first-line treatment.
Restoration of sleeping/morning erections should be
monitored and, if necessary, PDE5-I added. In adults with
LOH or any psychological distress, comorbidity, or drug-
related marginally reduced T level, a PDE5-I should be
administered first in the attempt to restore sexual function,
medications affecting sexuality should be discontinued
where possible, and finally, but most importantly, any
underlying conditions should be treated. Only then, if
androgens remain low, should TRT be used in combination
therapy (Fig. 3). This three-step approach, depicted in the
algorithm, protects against an inappropriate use of these
treatments. The EF improvement that can be expected
using TRT is small, compared with a PDE5-I, and it may
require several months, whereas the composite effects on
various sexual domains, including libido, are greater
especially in younger men. Based on the current evidence,
there are no major safety concerns that limit the use of TRT
in middle-age patients benefiting from treatment, not only
in terms of sexual life, but also on the several systemic
targets of the action of androgens, such as metabolism,
bone and musculature. In older men with proven CV risks,
TRT could yield to an increased number of adverse
effects, and for this reason treatment should be individu-
ally tailored. The 21st century approach to sexual
dysfunction must be based on the perspective of men’s
health as a whole.
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